The federal government filed a complaint to intervene in two consolidated False Claims Act suits against Johnson & Johnson alleging that the company paid millions of dollars in kickbacks to Omnicare pharmacies for prescribing its anti-psychotic drug Risperdal.  Sources close to the negotiations have said that a settlement is near and that Johnson & Johnson will pay $2.2 billion to resolve its civil and criminal liability, $1.2 billion more than the settlement the federal government reportedly rejected earlier this year.

Omnicare settled related allegations in November 2009 for $98 million.

Read the entire press release, “U.S. Files Suit Against Johnson & Johnson for Paying Kickbacks to Nation’s Largest Nursing Home Pharmacy”
Read the entire article, “J&J Said To Agree To $2.2 Billion Drug Marketing Accord”